Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  International Journal of Neuropsychopharmacology

• Publication date

  2002-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1017/S1461145702002857PMID 12135535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.

  1999cited by this paper
• A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.

  1996cited by this paper
• A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.

  1996cited by this paper
• Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia.

  1995cited by this paper
• Venlafaxine: measuring the onset of antidepressant action.

  1995cited by this paper
• A comparison of venlafaxine, trazodone, and placebo in major depression.

  1994cited by this paper
• Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.

  1994cited by this paper
• A double‐blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia

  1994cited by this paper
• Placebo‐Controlled Trial of Venlafaxine for the Treatment of Major Depression

  1991cited by this paper
• Venlafaxine in depressed outpatients.

  1991cited by this paper
• Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine

  1991cited by this paper
• Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

  1986cited by this paper

• Enriched environment ameliorates neurobehavioral abnormalities, hippocampal inflammation, and synaptic dysfunction in adult male mice exposed to intermittent hypoxia during pregnancy.

  2025cites this paper
• Norepinephrine system dysconnectivity in major depressive disorder: the effect of short term SSRI treatment.

  2025cites this paper
• The role of serotonin in depression—A historical roundup and future directions

  2024cites this paper
• Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study

  2021cites this paper
• The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect.

  2020cites this paper
• A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder

  2017cites this paper
• Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive‐ and impulsive‐like behaviors and on monoamine transmission in experimental temporal lobe epilepsy

  2016cites this paper
• Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants

  2015cites this paper
• Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram

  2015cites this paper
• Drug-, dose- and sex-dependent effects of chronic fluoxetine, reboxetine and venlafaxine on open-field behavior and spatial memory in rats.

  2015cites this paper
• Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis

  2014cites this paper
• Neurogeneza dorosłych a depresja Adult neurogenesis and depression

  2014cites this paper
• Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline

  2014cites this paper
• Findings of Bayesian Mixed Treatment Comparison Meta-Analyses: Comparison and Exploration Using Real-World Trial Data and Simulation

  2013cites this paper
• Fluoxetine versus other types of pharmacotherapy for depression.

  2013cites this paper
• Rapid sensitive validated UPLC–MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study

  2013cites this paper
• Murine Models for Developping an Individualized Neuropsychopharmacotherapy Based on the Behaviour Typology

  2013cites this paper
• Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies

  2012influential citation
• COMPARATIVE EFFECTIVENESS OF SECOND‐GENERATION ANTIDEPRESSANTS FOR ACCOMPANYING ANXIETY, INSOMNIA, AND PAIN IN DEPRESSED PATIENTS: A SYSTEMATIC REVIEW

  2012cites this paper
• The effect of inflammation on the central 5-HT system in mood disorders

  2012cites this paper
• Effects of Fluoxetine and Venlafaxine on the Salivary Gland - Experimental Study

  2012cites this paper
• How Should Primary Care Doctors Select Which Antidepressants to Administer?

  2012cites this paper
• The Effects of Reboxetine and Venlafaxine on ECG Variables in Depressed Patients

  2011cites this paper
• Drug Class Review: Second-Generation Antidepressants

  2011cites this paper
• Time to discontinuation among the three second‐generation antidepressants in a naturalistic outpatient setting of depression

  2011cites this paper
• Hijos de pacientes con trastorno afectivo bipolar tipo I de una población paisa: perfil psicopatológico y neuropsicológico

  2011cites this paper
• Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder

  2011cites this paper
• Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8‐week open‐label randomised paroxetine‐controlled trial

  2011cites this paper
• Neonatal Hair Analysis by Liquid Chromatography-High-Resolution Mass Spectrometry to Reveal Gestational Exposure to Venlafaxine

  2010cites this paper
• Comparison of SSRIs and SNRIs in major depressive disorder: a meta‐analysis of head‐to‐head randomized clinical trials

  2010cites this paper
• Sensitive Spectrofluorimetric Method of Analysis for Venlafaxine in Spiked Rat Plasma and Formulations

  2010cites this paper
• Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

  2010cites this paper
• The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression

  2009cites this paper
• Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity

  2009cites this paper
• Second Generation Antidepressants DRAFT-Update 4 January 2009

  2009cites this paper
• Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

  2009cites this paper
• Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?

  2009cites this paper
• Cost Effectiveness of Venlafaxine Compared with Generic Fluoxetine or Generic Amitriptyline in Major Depressive Disorder in the UK

  2009cites this paper
• Anxiety Disorders and Depression Comorbidity

  2008cites this paper
• Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians

  2008influential citation
• Direct versus indirect comparisons: A summary of the evidence

  2008cites this paper
• Behavioral Effects of Chronic Fluoxetine in BALB/cJ Mice Do Not Require Adult Hippocampal Neurogenesis or the Serotonin 1A Receptor

  2008cites this paper
• Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder.

  2008cites this paper
• Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials.

  2008cites this paper
• Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians.

  2008cites this paper
• Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.

  2008cites this paper
• Comparative Risk for Harms of Second Generation Antidepressants

  2008cites this paper
• Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection.

  2007cites this paper
• Which antidepressants have demonstrated superior efficacy? A review of the evidence

  2007cites this paper
• Escitalopram in the treatment of anxiety symptoms associated with depression

  2007cites this paper
• Limitations of contemporary antidepressants: tolerability.

  2007cites this paper
• Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.

  2007cites this paper
• Treatment of Major Depressive Disorder in Patients Failing Initial Therapy: An Excel-Based Pharmacoeconomic Model

  2007cites this paper
• A Budget-Impact and Cost-Effectiveness Model for Second-Line Treatment of Major Depression

  2007cites this paper
• Treatment of anxiety disorders with venlafaxine XR

  2006cites this paper
• Augmentation of the neurochemical and behavioural effects of SSRIs

  2006cites this paper
• Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.

  2006cites this paper
• Drug Class Review on Second Generation Antidepressants: Final Report

  2006cites this paper
• [Difficulties in the diagnosis and treatment of major depressive disorder with comorbid anxiety symptoms].

  2006cites this paper
• Anksiyete Belirtilerinin Eşlik Ettiği Majör Depresif Bozukluğun Tanı ve

  2006cites this paper
• Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data.

  2005cites this paper
• International Dosage Differences in Fluoxetine Clinical Trials

  2005cites this paper
• Fluoxetine versus other types of pharmacotherapy for depression.

  2005cites this paper
• Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis

  2005cites this paper
• Venlafaxin - bezpečnosť a tolerovanie pacientmi pri ambulantnej liečbe

  2005cites this paper
• Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder

  2005influential citation
• Side-Effect Profile of Fluoxetine in Comparison with Other SSRIs, Tricyclic and Newer Antidepressants: A Meta-Analysis of Clinical Trial Data

  2005cites this paper
• Qualitative review of SNRIs in anxiety.

  2004cites this paper
• A Double-Blind, Placebo-Controlled Study of a Flexible Dose of Venlafaxine ER in Adult Outpatients With Generalized Social Anxiety Disorder

  2004cites this paper
• Venlafaxine in the treatment of anxiety disorders

  2004cites this paper
• Long-term goals in the management of acute and chronic anxiety disorders.

  2004cites this paper
• The role of atypical antipsychotics in bipolar depression and anxiety disorders.

  2003cites this paper
• Comorbidity of depression and anxiety in the elderly

  2003cites this paper
• SNRIs Versus SSRIs: Mechanisms of Action in Treating Depression and Painful Physical Symptoms

  2003cites this paper
• Study of Efficacy, Remission and Tolerability of Fluoxetine Versus Desvenlafaxine in Patients with Depression in a Tertiary Care Hospital: An Open Labelled Randomized Interventional Comparative Study

  year unknowninfluential citation